Werewolf Therapeutics Reports Positive WTX-124 and WTX-330 Clinical Data
at www.tipranks.com (Mon, 9-Nov 9:48 AM)
HOWL and Ambros Announce Merger and $150M Private Placement, Paving a Path to Late-Stage Biotech Leadership
Market Chameleon (Fri, 21-Aug 9:51 AM)
